How many times per month can ferric carboxymaltose (FCM) be administered?

Ferric Carboxymaltose Dosing Frequency

In the United States, ferric carboxymaltose (FCM) is administered as two doses of 750 mg given one week apart, meaning you can give it twice per month with a minimum 7-day interval between doses. 1

Standard Dosing Protocol

The FDA-approved dosing schedule for FCM in the U.S. is straightforward:

• 750 mg per dose (the only available vial size in the U.S.)
• Two doses separated by at least 7 days
• Total cumulative dose: 1,500 mg (or 1,000 mg if only one dose is needed, though this wastes 500 mg from the second vial) 2, 1

Each infusion should be diluted in 100 mL normal saline and administered over 20-30 minutes 2.

International Dosing Differs

It's important to note that outside the United States, FCM is routinely given as a single 1,000 mg infusion rather than the split-dose U.S. protocol 2. This reflects differences in regulatory approval and available formulations rather than safety concerns.

Frequency of Repeat Courses

The timing of subsequent treatment courses depends entirely on the underlying cause of iron deficiency:

• If the cause is corrected (e.g., surgical treatment of bleeding source): A single course may suffice indefinitely 2

• If ongoing losses persist (heavy menstrual bleeding, gastrointestinal bleeding, inflammatory bowel disease): Repeat courses are necessary, with frequency determined by the rate of iron loss 2

• Reassessment timing: Check CBC and iron parameters (ferritin, transferrin saturation) 4-8 weeks after the last infusion to determine if additional treatment is needed 2

Critical Caveat: Hypophosphatemia Risk

FCM should be avoided in patients requiring frequent repeat infusions due to the risk of treatment-emergent hypophosphatemia 2. This is a unique and significant concern with FCM compared to other IV iron formulations.

The hypophosphatemia associated with FCM:

• Occurs in approximately 51-57% of patients after dosing 3, 4
• Can be moderate to severe 4
• Reaches its nadir around day 21 post-infusion 4
• Is accompanied by decreased 1,25-dihydroxyvitamin D and increased PTH 3, 4
• Can lead to prolonged complications including fatigue and osteomalacia with repeated dosing 5
• Generally resolves by day 91 but represents a cumulative risk with frequent administration 4

For patients needing chronic, repeated IV iron therapy, alternative formulations such as ferric derisomaltose (FDI), iron sucrose, or low-molecular-weight iron dextran should be strongly considered instead of FCM 2, 5.

Practical Algorithm

1. Initial course: Give 750 mg FCM, repeat in 7 days (total 1,500 mg)
2. Wait 4-8 weeks, then check hemoglobin, ferritin, and transferrin saturation 2
3. If iron deficiency persists:
   • Identify and address ongoing losses
   • If repeat courses will be needed frequently (monthly or more often), switch to a different IV iron formulation to avoid cumulative hypophosphatemia risk 2, 5
   • If only occasional repeat courses needed (every few months), FCM may be continued with phosphate monitoring

Monitor serum phosphate levels if giving repeat FCM courses, particularly in patients with chronic kidney disease, malnutrition, or conditions affecting bone health 3.